M. Kozloff

发表

Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer.

L. Chen, R. Evans, L. Ignacio, 1999, Radiation oncology investigations.

Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.

C. Rudin, M. Edelman, E. Vokes, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy.

J. Hainsworth, A. Grothey, S. Sarkar, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.

J. Berlin, A. Grothey, F. Kabbinavar, 2009, The oncologist.

A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

J. Dancey, E. Vokes, E. Cohen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Zinc abuse and sideroblastic anemia

M. Telfer, M. Kozloff, J. Ramadurai, 1993, American journal of hematology.

Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).

D. Sargent, A. Grothey, D. Purdie, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer

M. Socinski, M. Samant, F. Scappaticci, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, The oncologist.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Tae Won Kim, N. Segal, M. Fakih, 2019, The Lancet. Oncology.

Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2014, Pharmacoepidemiology and drug safety.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors

H. Hurwitz, J. Bendell, H. Pang, 2014, Investigational New Drugs.

Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

Efficacy of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.

W. Panje, R. Schilsky, R. Weichselbaum, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.

H. Burstein, C. Fabian, H. Parmar, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer

L. Saltz, F. Galimi, V. Haddad, 2013, Cancer.

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

J. Tabernero, J. Trojan, D. Melisi, 2019, Cancer Chemotherapy and Pharmacology.

Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): Preliminary results from a larger registry in the U.S

R. Robles, A. Grothey, F. Kabbinavar, 2005 .

Association of health-related quality of life with gender in patients with B-cell chronic lymphocytic leukemia

I. Flinn, C. Flowers, C. Pashos, 2013, Supportive Care in Cancer.

A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

H. Koeppen, L. Hart, J. Bendell, 2017, The oncologist.

Serious wound healing complications (sWHC) following surgery in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV): Results from the BRiTE observational cohort study (OCS)

D. Sargent, J. Berlin, A. Grothey, 2008 .

Incidence of serious bleeding events (sBE) in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: Results from the BRiTE observational cohort study (OCS)

D. Sargent, J. Berlin, A. Grothey, 2008 .

Anemia and transfusion

M. Telfer, M. Kozloff, C. Shapiro, 1994 .

Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results.

H. Hurwitz, Z. Wainberg, H. Burris, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intracavitary bleomycin for the control of malignant effusions

J. Bitran, C. Brown, M. Kozloff, 1981, Journal of surgical oncology.

A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer.

Z. Wainberg, A. Ashkenazi, W. Messersmith, 2013, Clinical colorectal cancer.

Phase I study of epidermal growth factor receptor (EGFR) inhibitor, erlotinib, and vascular endothelial growth factor monoclonal antibody, bevacizumab, in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

E. Vokes, E. Cohen, A. Mauer, 2004 .

E. Vokes, E. Cohen, A. Mauer, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment.

D. Goldenberg, C. Pinsky, G. Mills, 1995, Cancer research.

Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer

T. Hensing, T. Karrison, R. Brisson, 2017, Oncotarget.

Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck

E. Vokes, A. Argiris, D. Haraf, 2004, Clinical Cancer Research.

A Phase II Study of Erlotinib and Bevacizumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

E. Vokes, D. Yan, K. Stenson, 2009 .

A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC)

J. Dancey, E. Vokes, T. Karrison, 2005 .

Initial results from ARIES, a multi-indication bevacizumab (BV) observational cohort study (OCS): Characteristics of metastatic colorectal cancer (mCRC) patients (pts) receiving BV and chemotherapy (CT) in 2nd line

D. Sargent, A. Grothey, T. Bekaii-Saab, 2008 .

The safety of long-term bevacizumab use: Results from the BRiTE observational cohort study (OCS)

J. Berlin, A. Grothey, F. Kabbinavar, 2008 .

Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

E. Vokes, D. Taber, E. Cohen, 2008 .

Treatment of metastatic pancreatic and gastric adenocarcinomas with 5-fluorouracil, adriamycin, and mitomycin C (FAM).

J. Bitran, M. Kozloff, C. Shapiro, 1979, Cancer treatment reports.

ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC).

K. Takeshita, J. Schiller, J. Crawford, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer.

J. Tabernero, A. Cleverly, T. Macarulla, 2013 .

Effectiveness and safety of second-line (2L) irinotecan- and oxaliplatin-based regimens after first-line (1L) bevacizumab (BV)-containing treatment (tx) for metastatic colorectal cancer (mCRC): Results from the ARIES observational cohort study.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial.

E. Vokes, W. Stadler, H. Kindler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.

M. Blaney, Z. Wainberg, L. Naumovski, 2022, Future Oncology.

Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial.

E. Vokes, W. Stadler, H. Kindler, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.

M. Ratain, R. Weichselbaum, E. Vokes, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute nephrotoxicity following cis‐dichlorodiammine‐platinum

J. Bitran, M. Kozloff, C. Shapiro, 1982, Cancer.

Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): Results from the BRiTE observational cohort study

D. Sargent, J. Berlin, A. Grothey, 2008 .

Platinol (CDDP) and continuous intravenous infusion 5-fluorouracil in refractory stage IV breast cancer: a phase II study.

J. Bitran, M. Kozloff, R. Desser, 1990, Cancer investigation.

Immunologic Status of Patients in Remission from Hodgkin's Disease and Disseminated Malignancies

M. Telfer, J. Bitran, M. Kozloff, 1987 .

Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC).

G. Wilding, C. Logothetis, A. Zurita, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1231 A phase I study of axitinib (AG-013736) combined with paclitaxel/carboplatin (P/C), gemcitabine/cisplatin (Gem/Cis) or pemetrexed/cisplatin (Pem/Cis) in patients (pts) with solid tumours, including advanced non-small cell lung cancer (NSCLC)

R. Cohen, M. Tortorici, A. Olszanski, 2009 .

Mononeuropathy multiplex due to infiltration of lymphoma in hematologic remission

D. Walk, M. Kozloff, C. Shapiro, 1998, Muscle & nerve.

An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer

M. Collier, K. Kern, K. Miller, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer

R. Salgia, H. Lenz, F. D. de Sauvage, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.

J. Subramanian, R. Govindan, R. Salgia, 2012, Clinical lung cancer.

Phase II study of mitoxantrone and ketoconazole for hormone‐refractory prostate cancer

R. Bergan, M. Pins, B. Jovanovic, 2006, Cancer.

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

C. Flowers, S. de Vos, L. Swinnen, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Ethnic Differences and Functional Analysis of MET Mutations in Lung Cancer

Jie Liang, D. Nicolae, J. Minna, 2009, Clinical Cancer Research.

A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer

G. Gordon, P. Ma, E. Cohen, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.

M. Ratain, C. Nabhan, W. Stadler, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.

A. Grothey, F. Kabbinavar, P. Flynn, 2012, European journal of cancer.

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

J. Tabernero, J. Trojan, H. Oettle, 2018, British Journal of Cancer.

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.

G. Wilding, C. Logothetis, D. George, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using UGT1A1 Genotype–Guided Dosing

T. Karrison, M. Zalupski, A. Sadiq, 2019, Clinical Cancer Research.

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study.

J. Dancey, E. Vokes, T. Seiwert, 2009, The Lancet. Oncology.

Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: impact on the natural history of the disease.

W. Panje, R. Weichselbaum, E. Vokes, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer

W. Panje, R. Weichselbaum, E. Vokes, 1990, Cancer.

A UGT1A1 genotype‐guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies

T. Karrison, H. Kindler, B. Polite, 2019, Cancer.

A prospective trial of stereotactic body radiation therapy for unresectable pancreatic cancer testing ablative doses.

M. Posner, H. Kindler, S. Liauw, 2020, Journal of gastrointestinal oncology.

Real‐world clinical experience in the Connect® chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres

I. Flinn, C. Flowers, C. Nabhan, 2016, British journal of haematology.

Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

G. Sledge, K. Miller, M. Kozloff, 2010 .

Phase II study of sunitinib malate in head and neck squamous cell carcinoma

E. Vokes, D. Taber, T. Karrison, 2010, Investigational New Drugs.

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer

J. Tabernero, J. Trojan, H. Oettle, 2018, British Journal of Cancer.

Prognostic value of the estrogen receptor level in pathologic stage I and II adenocarcinoma of the breast

W. Recant, Richard W. Evans, J. Bitran, 1982, Journal of surgical oncology.

SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results.

H. Parmar, E. Mayer, H. Burstein, 2009 .

Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC).

J. Bendell, A. Ashkenazi, M. Kozloff, 2012 .

Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC).

Z. Wainberg, A. Ashkenazi, W. Messersmith, 2011 .

Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

G. Salles, M. Hallek, S. Stilgenbauer, 2015 .

Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study

M. Talamonti, M. Posner, J. Matthews, 2018, Journal of surgical oncology.

A Phase II trial of induction Cisplatin, 5-FU, Leucovorin, and Interferon α-2B (PFL-α) followed by concurrent Hydroxyurea, 5-FU and radiation for Stage IV squamous cell cancers of the head and neck (HNC)

W. Panje, R. Weichselbaum, D. Haraf, 1994 .

Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.

W. Panje, M. Ratain, R. Weichselbaum, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, 5-Fluorouracil and high dose oral Leucovorin (PFL) with Methotrexate and Piritrexim as Neo-Adjuvant chemotherapy for head and neck cancer

W. Panje, R. Weichselbaum, E. Vokes, 1991 .

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Jeffrey Bozeman, J. Dancey, E. Vokes, 2012, Clinical Cancer Research.

Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer

C. Rudin, J. Villano, E. Vokes, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours

R. Herbst, R. Cohen, J. de Castro Carpeno, 2012, British Journal of Cancer.

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.

A. Dachman, E. Vokes, W. Stadler, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE).

J. Hainsworth, A. Grothey, P. Flynn, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II, double-blind study of galunisertib+gemcitabine (GG) vs gemcitabine+placebo (GP) in patients (pts) with unresectable pancreatic cancer (PC).

J. Tabernero, J. Trojan, H. Oettle, 2016 .

Personalized colon cancer care in 2010.

H. Kindler, D. Catenacci, B. Polite, 2011, Seminars in oncology.

A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.

O. Harismendy, E. Vokes, T. Seiwert, 2022, Clinical Cancer Research.

Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.

A. Rademaker, R. Weichselbaum, E. Vokes, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploring racial differences in outcome and treatment for metastatic colorectal cancer

D. Sargent, J. Berlin, A. Grothey, 2012, Cancer.

Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer

O. Olopade, J. Dancey, R. Salgia, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE)

A. Grothey, J. Yi, D. Purdie, 2007 .

Bevacizumab (BV) plus chemotherapy (CT) in second-line metastatic colorectal cancer (mCRC): Initial results from ARIES, a second BV observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2010 .

3021 POSTER Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE)

D. Sargent, A. Grothey, D. Purdie, 2007 .

Exploring racial differences in outcome for metastatic colorectal cancer: Results from a large prospective observational cohort study (BRiTE).

B. Polite, M. Kozloff, A. Sing, 2010 .

Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

J. Blay, A. Lluch, S. Verma, 2014, BMC Cancer.

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours

R. Herbst, R. Cohen, M. Tortorici, 2012, British Journal of Cancer.

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of Clinical Oncology.

Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort Study

J. Berlin, A. Grothey, F. Kabbinavar, 2010, Oncology.

Effectiveness of first- or second-line bevacizumab (BV) treatment (tx) in elderly patients (pts) with metastatic colorectal cancer (mCRC) in ARIES, an observational cohort study (OCS).

A. Grothey, H. Hurwitz, T. Bekaii-Saab, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetuximab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis.

E. Vokes, H. Hochster, H. Kindler, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): A phase II precision medicine trial (NCT02213289).

H. Kindler, B. Polite, A. Amico, 2018 .

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

J. Tabernero, N. Segal, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity and safety of sunitinib in combination with trastuzumab for the treatment of metastatic breast cancer: initial results from a phase II study.

J. Blay, A. Lluch, S. Verma, 2009 .

A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).

L. Hart, J. Bendell, D. Shames, 2015 .

Phase II trial of sequential bevacizumab (B), erlotinib (E) and chemotherapy for first line treatment of clinical stage IIIB or IV non-small cell lung cancer (NSCLC)

M. Maitland, R. Govindan, R. Salgia, 2008 .

Variation in health-related quality of life (HRQOL) by ECOG performance status (PS) and fatigue among patients with chronic lymphocytic leukemia (CLL).

I. Flinn, C. Flowers, C. Pashos, 2012 .

Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ® CLL Disease Registry

I. Flinn, C. Flowers, T. Kipps, 2011 .

VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON‐HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY

L. Swinnen, S. Wong, J. Ross, 2017 .

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

H. Hurwitz, J. Bendell, M. Morse, 2012, Journal of Clinical Oncology.

IMpower150: Exploratory efficacy analysis in patients (pts) with bulky disease.

J. Subramanian, K. Sabbath, E. Bernicker, 2020 .

Profferred Paper Abstracts: Session C3: Combined Modality Therapy in NSCLC II: Wednesday, September 5: Combined Modality Therapy in NSCLC II, Wed, 10:30 - 12:15C3-01: Phase I Trial of Erlotinib-based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer

E. Vokes, D. Haraf, N. Choong, 2007 .

Serious arterial thromboembolic events (sATE) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV): Results from the BRiTE registry

A. Grothey, J. Yi, D. Purdie, 2007 .

Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.

G. Wilding, C. Logothetis, D. George, 2012 .

A Dose-Escalation Study of Venetoclax (ABT-199/GDC-0199) in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

C. Flowers, L. Swinnen, J. Cordero, 2015 .

Multimodality therapy of stage III adenocarcinoma of the breast

W. Recant, J. Bitran, H. Rochman, 1983, Journal of surgical oncology.

A randomized phase II study of anti-PD1 antibody [MK-3475 (Pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced merkel cell carcinoma (Alliance A091605).

H. Al-Hallaq, S. Yom, G. Schwartz, 2018 .

Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer

M. Maitland, D. Carbone, C. Chung, 2014, BMC Cancer.

Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.

W. Panje, E. Vokes, M. Collier, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia

G. Salles, M. Hallek, G. Lozanski, 2016 .

Regarding ‘Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study’

F. Kabbinavar, M. Kozloff, 2011, Oncology.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

O. V. Matorin, Kelvin K. W. Chan, Sung-Bae Kim, 2019, The Lancet.

Distinct patterns of PSA modulation by single-agent sunitinib before combination with docetaxel and prednisone in patients with metastatic castrate-resistant prostate cancer (CRPCa)

C. Logothetis, C. Ryan, A. Zurita, 2007 .

3049 POSTER Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer (mCRC) treated with bevacizumab (BV) plus chemotherapy (CT)

J. Hainsworth, A. Grothey, J. Yi, 2007 .

Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer

J. Villano, E. Vokes, A. Mauer, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

R. Bose, H. Rugo, D. Tripathy, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX as first-line therapy in patients with metastatic gastroesophageal cancers (GEC).

J. Picus, A. Lockhart, K. Lim, 2015 .

The GAIN-C study (BP25438): Randomized phase II trial of RG7160 (GA201) plus FOLFIRI, compared to cetuximab plus FOLFIRI or FOLFIRI alone in second-line KRAS wild type (WT) or mutant metastatic colorectal cancer (mCRC).

J. Tabernero, J. Bridgewater, B. Markman, 2012 .